ATC code none PubChem CID 115358 UNII 262P8GS9L9 | CAS Number 106635-80-7 ChemSpider 103196 Molar mass 463.493 g/mol | |
 | ||
Synonyms Etaquine, WR 238605, SB-252263 | ||
Tafenoquine malaria drug development
Tafenoquine is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is being investigated as a potential treatment for malaria, as well as for malaria prevention.
Contents
The proposed indication for tafenoquine is for treatment of the hypnozoite stages of Plasmodium vivax and Plasmodium ovale that are responsible for relapse of these malaria species even when the blood stages are successfully cleared. This is only now achieved by administration of daily primaquine for 14 days. The main advantage of tafenoquine is that it has a long half-life (2–3 weeks) and therefore a single treatment may be sufficient to clear hypnozoites. The shorter regimen has been described as an advantage.
Like primaquine, tafenoquine causes hemolysis in people with G6PD deficiency. Indeed, the long half-life of tafenoquine suggests that particular care should be taken to ensure that individuals with severe G6PD deficiency do not receive the drug.
The dose of tafenoquine has not been firmly established, but for the treatment of Plasmodium vivax malaria, a dose of 800 mg over three days has been used.